ORKA
Oruka Therapeutics Inc.

182
Loading...
Loading...
News
all
press releases
News Placeholder
MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgrades
Wolfe Research compared MoonLake’s setback to Acelyrin’s HS trial failure, noting that Acelyrin’s stock never rebounded despite later progress in other programs.
Stocktwits·12d ago

Latest ORKA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.